Chemo may be preferred option for some with advanced prostate cancer
the ONA take:
According to the results of a small clinical trial published online in JAMA Oncology, researchers from Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute in Baltimore, Maryland, have found that men with advanced prostate cancer who possess the androgen receptor splice variant-7 (AR-V7) respond just as well to chemotherapy as those who lack AR-V7.
The AR-V7 gene variant has been shown to confer resistance to enzalutamide or abiraterone, two hormonal drugs used to treated castration-resistant prostate cancer; however, the study found that patients with the variant respond similarly to docetaxel or cabazitaxel compared with those without the gene variant.
"Our study shows that men who have the AR-V7 gene variant and usually don't respond to either abiraterone or enzalutamide, are not at a disadvantage when given chemotherapy drugs," says Emmanuel Antonarakis, M.D., an oncologist at the Kimmel Cancer Center.
The researchers are currently working to develop and validate a test to detect AR-V7 in patients with advanced prostate cancer to better inform treatment decisions.
Men with advanced prostate cancer who possess AR-V7 respond just as well to chemotherapy as those who lack AR-V7.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|